Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Neurofilament light chain level is a weak risk factor for the development of MS

  • Arrambide, Georgina|||0000-0002-2657-5510
  • Espejo, Carmen|||0000-0001-9949-5901
  • Eixarch, Herena|||0000-0001-7525-9533
  • Villar, Luisa M.|||0000-0002-9067-3668
  • Alvarez-Cermeño, José C.|||0000-0002-1345-2837
  • Picón, Carmen
  • Kuhle, Jens|||0000-0002-6963-8892
  • Disanto, Giulio
  • Kappos, Ludwig|||0000-0003-4175-5509
  • Sastre-Garriga, Jaume|||0000-0002-1589-2254
  • Pareto, Deborah|||0000-0001-7356-3769
  • Simon, Eva
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Río, Jordi|||0000-0003-4546-7627
  • Nos, Carlos|||0000-0002-3830-4910
  • Tur, Carmen|||0000-0003-1849-3184
  • Castilló, Joaquín|||0000-0002-8951-6315
  • Vidal-Jordana, Angela|||0000-0002-7270-5507
  • Galan, Ingrid|||0000-0001-5774-4260
  • Arévalo, María Jesús|||0000-0003-0626-5555
  • Auger, Cristina|||0000-0001-9846-4767
  • Rovira, Alex|||0000-0002-2132-6750
  • Montalban, Xavier|||0000-0002-0098-9918
  • Tintoré, Mar|||0000-0001-9999-5359
To determine the prognostic value of selected biomarkers in clinically isolated syndromes (CIS) for conversion to multiple sclerosis (MS) and disability accrual. Data were acquired from 2 CIS cohorts. The screening phase evaluated patients developing clinically definite MS (CIS-CDMS) and patients who remained as CIS during a 2-year minimum follow-up (CIS-CIS). We determined levels of neurofascin, semaphorin 3A, fetuin A, glial fibrillary acidic protein, and neurofilament light (NfL) and heavy chains in CSF (estimated mean [95% confidence interval; CI]). We evaluated associations between biomarker levels, conversion, disability, and magnetic resonance parameters. In the replication phase, we determined NfL levels (n = 155) using a 900 ng/L cutoff. Primary endpoints in uni- and multivariate analyses were CDMS and 2010 McDonald MS. The only biomarker showing significant differences in the screening was NfL (CIS-CDMS 1,553.1 [1,208.7-1,897.5] ng/L and CIS-CIS 499.0 [168.8-829.2] ng/L, p < 0.0001). The strongest associations were with brain parenchymal fraction change (r = -0.892) and percentage brain volume change (r = -0.842) at 5 years. NfL did not correlate with disability. In the replication phase, more NfL-positive patients, according to the cutoff, evolved to MS. Every 100-ng/L increase in NfL predicted CDMS (hazard ratio [HR] = 1.009, 95% CI 1.005-1.014) and McDonald MS (HR = 1.009, 95% CI 1.005-1.013), remaining significant for CDMS in the multivariate analysis (adjusted HR = 1.005, 95% CI 1.000-1.011). This risk was lower than the presence of oligoclonal bands or T2 lesions. NfL is a weak independent risk factor for MS. Its role as an axonal damage biomarker may be more relevant as suggested by its association with medium-term brain volume changes.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Serum Biomarker gMS-Classifier2, Predicting Conversion to Clinically Definite Multiple Sclerosis

  • Arrambide, Georgina|||0000-0002-2657-5510
  • Espejo, Carmen|||0000-0001-9949-5901
  • Yarden, Jennifer
  • Fire, Ella
  • Spector, Larissa
  • Dotan, Nir
  • Dukler, Avinoam
  • Rovira, Alex|||0000-0002-2132-6750
  • Montalban, Xavier|||0000-0002-0098-9918
  • Tintoré, Mar|||0000-0001-9999-5359
Anti-glycan antibodies can be found in autoimmune diseases. IgM against glycan P63 was identified in clinically isolated syndromes (CIS) and included in gMS-Classifier2, an algorithm designed with the aim of identifying patients at risk of a second demyelinating attack. To determine the value of gMS-Classifier2 as an early and independent predictor of conversion to clinically definite multiple sclerosis (CDMS). Data were prospectively acquired from a CIS cohort. gMS-Classifier2 was determined in patients first seen between 1995 and 2007 with ≥ two 200 µL serum aliquots (N = 249). The primary endpoint was time to conversion to CDMS at two years, the factor tested was gMS-Classifier2 status (positive/negative) or units; other exploratory time points were 5 years and total time of follow-up. Seventy-five patients (30.1%) were gMS-Classifier2 positive. Conversion to CDMS occurred in 31/75 (41.3%) of positive and 45/174 (25.9%) of negative patients (p = 0.017) at two years. Median time to CDMS was 37.8 months (95% CI 10.4-65.3) for positive and 83.9 months (95% CI 57.5-110.5) for negative patients. gMS-Classifier2 status predicted conversion to CDMS within two years of follow-up (HR = 1.8, 95% CI 1.1-2.8; p = 0.014). gMS-Classifier2 units were also independent predictors when tested with either Barkhof criteria and OCB (HR = 1.2, CI 1.0-1.5, p = 0.020) or with T2 lesions and OCB (HR = 1.3, CI 1.1-1.5, p = 0.008). Similar results were obtained at 5 years of follow-up. Discrimination measures showed a significant change in the area under the curve (ΔAUC) when adding gMS-Classifier2 to a model with either Barkhof criteria (ΔAUC 0.0415, p = 0.012) or number of T2 lesions (ΔAUC 0.0467, p = 0.009), but not when OCB were added to these models. gMS-Classifier2 is an independent predictor of early conversion to CDMS and could be of clinical relevance, particularly in cases in which OCB are not available